Phase II multicenter trial: first-line immunochemotherapy with or without radiotherapy in metastatic esophageal squamous cell cancer (SCR-ESCC-01)
Authors:
- 8 November 2023
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 19 (34) , 2291-2296
Abstract
This randomized phase II trial (NCT05978193) combines low-dose radiotherapy (LDRT) and conventionally fractionated radiotherapy (CFRT) with immunochemotherapy for metastatic esophageal squamous cel...Keywords
This publication has 14 references indexed in Scilit:
- Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysisInternational Immunopharmacology, 2022
- Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trialCancer Cell, 2022
- Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell CarcinomaJAMA, 2021
- Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to ImmunotherapyCancer Discovery, 2021
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 studyThe Lancet, 2021
- Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trialsThe Lancet Respiratory Medicine, 2021
- Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2019
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trialThe Lancet Oncology, 2017
- Radiotherapy combination opportunities leveraging immunity for the next oncology practiceCA: A Cancer Journal for Clinicians, 2016